NetworkNewsBreaks – INmune Bio Inc.’s (NASDAQ:
Post# of 33
(Total Views: 290)
Posted On: 07/19/2019 5:59:07 PM
NetworkNewsBreaks – INmune Bio Inc.’s (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflammation to Treat Alzheimer’s Disease
INmune Bio (NASDAQ: INMB) is an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, such as Alzheimer’s disease (“AD”). A recent article discussing the company reads, “An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which it could be used to offer reliable AD treatments have both been overlooked. Numerous inflammatory markers are found in AD patients, and several studies establish a link between chronic inflammation and the development of AD. . . . XPro1595 works by targeting the microglial immune cells of the brain. These cells are activated in many AD patients. They cause neuroinflammation that kills nerve cells and promotes synaptic dysfunction. Combined, these two effects lead to dementia in people with AD.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio (NASDAQ: INMB) is an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, such as Alzheimer’s disease (“AD”). A recent article discussing the company reads, “An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which it could be used to offer reliable AD treatments have both been overlooked. Numerous inflammatory markers are found in AD patients, and several studies establish a link between chronic inflammation and the development of AD. . . . XPro1595 works by targeting the microglial immune cells of the brain. These cells are activated in many AD patients. They cause neuroinflammation that kills nerve cells and promotes synaptic dysfunction. Combined, these two effects lead to dementia in people with AD.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)INmune Bio Inc. (INMB) Stock Research Links
Scroll down for more posts ▼